LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Chiusa

28.71 -3.75

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.21

Massimo

29.89

Metriche Chiave
By Trading Economics
Entrata	43M 13M
Vendite	29M 107M
EPS	0.25
Margine di Profitto	12.139
Dipendenti	524
EBITDA	16M 8.2M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+107.77% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-6.7M 1.4B
Apertura precedente	32.46
Chiusura precedente	28.71

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

27.895 / 30.16 Supporto e resistenza

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 mag 2026, 16:33 UTC

Utili

I principali Market Mover

Webull Shares Slide on 1Q Loss, Soaring Costs

22 mag 2026, 21:10 UTC

Utili

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 19:47 UTC

Utili

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mag 2026, 19:17 UTC

Discorsi di Mercato

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mag 2026, 18:38 UTC

Discorsi di Mercato

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mag 2026, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mag 2026, 18:09 UTC

Discorsi di Mercato

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mag 2026, 17:58 UTC

Discorsi di Mercato

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 mag 2026, 17:03 UTC

Discorsi di Mercato

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 mag 2026, 16:54 UTC

Discorsi di Mercato

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 16:16 UTC

Discorsi di Mercato

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

22 mag 2026, 15:55 UTC

Discorsi di Mercato

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 mag 2026, 15:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 mag 2026, 15:42 UTC

Discorsi di Mercato

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 mag 2026, 15:35 UTC

Discorsi di Mercato

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

107.77% in crescita

Previsioni per 12 mesi

Media 62.33 USD 107.77%

Alto 100 USD

Basso 33 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

27.895 / 30.16Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.